158 related articles for article (PubMed ID: 22487899)
21. TranScreen-N: Method for rapid screening of trans-ungual drug delivery enhancers.
Murthy SN; Vaka SR; Sammeta SM; Nair AB
J Pharm Sci; 2009 Nov; 98(11):4264-71. PubMed ID: 19363796
[TBL] [Abstract][Full Text] [Related]
22. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
[TBL] [Abstract][Full Text] [Related]
23. Controlled-release injectable containing terbinafine/PLGA microspheres for onychomycosis treatment.
Angamuthu M; Nanjappa SH; Raman V; Jo S; Cegu P; Murthy SN
J Pharm Sci; 2014 Apr; 103(4):1178-83. PubMed ID: 24497012
[TBL] [Abstract][Full Text] [Related]
24. Iontophoretic terbinafine delivery in onychomycosis: questionable nail growth.
Oon HH; Tan HH
Br J Dermatol; 2010 Mar; 162(3):699-700. PubMed ID: 20030642
[No Abstract] [Full Text] [Related]
25. Formulation development and optimization of transungual drug delivery system of terbinafine hydrochloride for the treatment of onychomycosis.
Patel MM; Vora ZM
Drug Deliv Transl Res; 2016 Jun; 6(3):263-75. PubMed ID: 26926242
[TBL] [Abstract][Full Text] [Related]
26. Iontophoresis application for drug delivery in high resistivity membranes: nails and teeth.
Martins Andrade JF; da Cunha Miranda T; Cunha-Filho M; Taveira SF; Gelfuso GM; Gratieri T
Drug Deliv Transl Res; 2023 May; 13(5):1272-1287. PubMed ID: 36209312
[TBL] [Abstract][Full Text] [Related]
27. In vitro permeability of a model protein across ocular tissues and effect of iontophoresis on the transscleral delivery.
Tratta E; Pescina S; Padula C; Santi P; Nicoli S
Eur J Pharm Biopharm; 2014 Sep; 88(1):116-22. PubMed ID: 24816128
[TBL] [Abstract][Full Text] [Related]
28. Studies in drug transport vs. current in iontophoretic onychomycosis treatment.
Barsness M; Davis SP; Etheredge R; Chang K; Kim H
Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():289-94. PubMed ID: 19964736
[TBL] [Abstract][Full Text] [Related]
29. Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models.
Kalaria DR; Patel P; Merino V; Patravale VB; Kalia YN
Mol Pharm; 2013 Nov; 10(11):4322-9. PubMed ID: 24028565
[TBL] [Abstract][Full Text] [Related]
30. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
Nolan LM; Corish J; Corrigan OI; Fitzpatrick D
Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130
[TBL] [Abstract][Full Text] [Related]
31. Bilayered nail lacquer of terbinafine hydrochloride for treatment of onychomycosis.
Shivakumar HN; Vaka SR; Madhav NV; Chandra H; Murthy SN
J Pharm Sci; 2010 Oct; 99(10):4267-76. PubMed ID: 20737634
[TBL] [Abstract][Full Text] [Related]
32. A platform for predicting and enhancing model drug delivery across the human nail plate.
Vaka SR; Murthy SN; O'Haver JH; Repka MA
Drug Dev Ind Pharm; 2011 Jan; 37(1):72-9. PubMed ID: 20545509
[TBL] [Abstract][Full Text] [Related]
33. Onychopharmacokinetics of terbinafine hydrochloride penetration from a novel topical formulation into the human nail in vitro.
Hui X; Lindahl Å; Lamel S; Maibach HI
Drug Dev Ind Pharm; 2013 Sep; 39(9):1401-7. PubMed ID: 22873754
[TBL] [Abstract][Full Text] [Related]
34. In vivo transungual iontophoresis: effect of DC current application on ionic transport and on transonychial water loss.
Dutet J; Delgado-Charro MB
J Control Release; 2009 Dec; 140(2):117-25. PubMed ID: 19709638
[TBL] [Abstract][Full Text] [Related]
35. Iontophoretic drug delivery for the treatment of scars.
Manda P; Angamuthu M; Hiremath SR; Raman V; Murthy SN
J Pharm Sci; 2014 Jun; 103(6):1638-42. PubMed ID: 24648369
[TBL] [Abstract][Full Text] [Related]
36. Transungual drug delivery: current status.
Elkeeb R; AliKhan A; Elkeeb L; Hui X; Maibach HI
Int J Pharm; 2010 Jan; 384(1-2):1-8. PubMed ID: 19819318
[TBL] [Abstract][Full Text] [Related]
37. Transdermal iontophoretic delivery of propofol: a general anaesthetic in the form of its phosphate salt.
Juluri A; Peddikotla P; Repka MA; Murthy SN
J Pharm Sci; 2013 Feb; 102(2):500-7. PubMed ID: 23175436
[TBL] [Abstract][Full Text] [Related]
38. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.
Faergemann J; Zehender H; Denouël J; Millerioux L
Acta Derm Venereol; 1993 Aug; 73(4):305-9. PubMed ID: 7904107
[TBL] [Abstract][Full Text] [Related]
39. Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis.
Hao J; Li SK
J Pharm Sci; 2008 Feb; 97(2):893-905. PubMed ID: 17683062
[TBL] [Abstract][Full Text] [Related]
40. Terbinafine: novel formulations that potentiate antifungal activities.
Ma Y; Chen X; Guan S
Drugs Today (Barc); 2015 Mar; 51(3):197-208. PubMed ID: 25876563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
